Last ¥1,803 JPY
Change Today -13.00 / -0.72%
Volume 575.1K
4508 On Other Exchanges
Symbol
Exchange
Berlin
Tokyo
OTC US
OTC US
OTC US
As of 1:00 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

mitsubishi tanabe pharma (4508) Snapshot

Open
¥1,807
Previous Close
¥1,816
Day High
¥1,827
Day Low
¥1,800
52 Week High
11/18/14 - ¥1,872
52 Week Low
04/14/14 - ¥1,365
Market Cap
1.0T
Average Volume 10 Days
1.4M
EPS TTM
¥88.01
Shares Outstanding
561.4M
EX-Date
03/27/15
P/E TM
20.5x
Dividend
¥40.00
Dividend Yield
2.22%
Current Stock Chart for MITSUBISHI TANABE PHARMA (4508)

Related News

No related news articles were found.

mitsubishi tanabe pharma (4508) Related Businessweek News

No Related Businessweek News Found

mitsubishi tanabe pharma (4508) Details

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan and internationally. The company offers autoimmune drugs, including Remicade agent for rheumatoid arthritis and Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis; and Simponi agent for rheumatoid arthritis. It also provides drugs for diabetes and kidney diseases, such as Kremezin agent for chronic renal failure; and Tanatril agent for hypertension and diabetic nephropathy with type I diabetes mellitus, etc. In addition, the company offers drugs for central nervous system diseases comprising Radicut, a cerebral neuroprotectant; Ceredist agent for spinocerebellar degeneration; Depas, an anti-anxiety agent; and Lexapro, an anti-depressant agent. Further, it provides Maintate agent for treatment of hypertension, angina pectoris, ventricular extrasystole, chronic heart failure, and atrial fibrillation; Talion agent for allergic disorders; Urso agent for the improvement of hepatic, biliary, and digestive function; Anplag, an anti-platelet agent; and Herbesser, an agent for angina pectoris and hypertension. Additionally, the company offers vaccines, such as TETRABIK, a combined vaccine for diphtheria, pertussis, tetanus, and poliomyelitis; and influenza. It also provides over-the-counter products, including herbal and digestive medicines, as well as oral solutions for tonic and nutritional supplement; oral agent for allergic rhinitis; and products for the treatment of skin conditions and recurrent vaginal candidiasis. The company also offers pharmaceutical information and real estate management services; sells generic pharmaceuticals, chemicals, etc.; invests in bio-ventures; and is involved in distribution and warehouse operations. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.

9,065 Employees
Last Reported Date: 06/20/14
Founded in 1678

mitsubishi tanabe pharma (4508) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mitsubishi tanabe pharma (4508) Key Developments

Mitsubishi Tanabe Pharma Corporation, Q2 2015 Earnings Call, Oct 30, 2014

Mitsubishi Tanabe Pharma Corporation, Q2 2015 Earnings Call, Oct 30, 2014

Mitsubishi Tanabe Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2014; Revises Earnings Guidance for the Full Year of 2014

Mitsubishi Tanabe reported earnings results for the second quarter and six months ended September 30, 2014. For the quarter, the company posted a 13.9% rise in net income in its second fiscal quarter, driven by growth in pharmaceutical sales. The company earned net income of JPY 32.5 billion compared to JPY 28.5 billion in the year-ago period. Net sales were JPY 198.9 billion, down 1.9% from JPY 202.8 billion for the year-ago period. The company's earnings continue to show a decline in domestic sales of its ethical drugs in the face of increasing competition from generics, and the National Health Insurance (NHI) price revisions in April. For the six months, the company’s net sales were JPY 198.9 billion against JPY 202.8 billion a year ago. Operating income was JPY 35 billion against JPY 30.5 billion a year ago. The company revised earnings guidance for the full year of 2014. For the period, the company maintained its lower forecasts, which are now expected to come in at JPY 406 billion, 0.7% lower than originally expected.

Mitsubishi Tanabe Pharma Corporation to Report Q2, 2015 Results on Oct 29, 2014

Mitsubishi Tanabe Pharma Corporation announced that they will report Q2, 2015 results on Oct 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4508:JP ¥1,803.00 JPY -13.00

4508 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4508.
View Industry Companies
 

Industry Analysis

4508

Industry Average

Valuation 4508 Industry Range
Price/Earnings 19.2x
Price/Sales 2.3x
Price/Book 1.2x
Price/Cash Flow 15.3x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MITSUBISHI TANABE PHARMA, please visit www.mt-pharma.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.